Clinical Trial Update: A Study of Efgartigimod in Patients With IgG4-Related Disease [Phase 2]

View source ↗

Summary

This is a Phase 2 study of efgartigimod in patients with IgG4-related disease, currently recruiting. The trial is sponsored by Stanford University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: Stanford University | Conditions: IgG4-related Disease | Phase 2 | Status: RECRUITING